Previous 10 |
home / stock / tryp:cc / tryp:cc news
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL Canada NewsWire Phase II trial to determine efficacy of psilocybin in combination with psychotherapy for potential treatment of Binge Eating Disorder SAN DIEGO , ...
(TheNewswire) SAN DIEGO, CALIFORNIA – TheNewswire - April 22, 2022 – Tryp Therapeutics (CSE:TRYP) (OTC:TRYPF) (“ Tryp ” or the “ Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the first patient enrolled to evaluate its clinical candidate, TRP-8802, in a clinical trial. The study will be con...
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida Canada NewsWire Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc. Company Name:
TRYP:CC Stock Symbol:
CNQC Market:
Tryp Therapeutics Inc. Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of arrangement (the “...